Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma

A Kharazmi; H Nielsen; D Hovgaard; N Borregaard; N I Nissen

Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma

A Kharazmi, H Nielsen, D Hovgaard, N Borregaard, N I Nissen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

18 Citationer (Scopus)

Abstract

Udgivelsesdato: 1991-Apr

Originalsprog	Engelsk
Tidsskrift	European Journal of Clinical Investigation
Vol/bind	21
Udgave nummer	2
Sider (fra-til)	219-24
Antal sider	5
ISSN	0014-2972
Status	Udgivet - 1991

Bibliografisk note

Keywords: Cell Degranulation; Chemotaxis, Leukocyte; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Luminescent Measurements; Lymphoma, Non-Hodgkin; Monocytes; Neutrophils; Recombinant Proteins

Citationsformater

@article{423d3ce0207b11df8ed1000ea68e967b,

title = "Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma",

abstract = "Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to inhibit the chemotaxis and enhance the oxidative burst response of human neutrophils in vitro. The present study describes the effect of recombinant GM-CSF on the neutrophil and monocyte function in patients with lymphoma undergoing GM-CSF treatment. Patients with either Hodgkin's or non-Hodgkin's lymphoma were treated with various dosages (2-16 micrograms kg-1 body weight per day for 5 days) of rhGM-CSF by intravenous or subcutaneous route. Prior to and on day 5 of rhGM-CSF treatment, neutrophil and monocyte chemotaxis and chemiluminescence responses to f-Met-Leu-Phe, zymosan activated serum (ZAS) and opsonized zymosan (OZ) were determined. It was observed that chemotactic response of neutrophils to f-Met-Leu-Phe and ZAS was reduced, whereas the chemiluminescence response of both cell types to f-Met-Leu-Phe and zymosan was enhanced by up to 43-fold. rhGM-CSF treatment did not affect degranulation of the neutrophils as measured by release of vitamin B12 binding protein. Degree of modulation of neutrophil and monocyte function by rhGM-CSF was independent of rhGM-CSF dosages administered. These data suggest that phagocytic defence system may be enhanced by GM-CSF treatment and that this cytokine may be a useful therapeutic adjunct in compromised patients.",

author = "A Kharazmi and H Nielsen and D Hovgaard and N Borregaard and Nissen, {N I}",

note = "Keywords: Cell Degranulation; Chemotaxis, Leukocyte; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Luminescent Measurements; Lymphoma, Non-Hodgkin; Monocytes; Neutrophils; Recombinant Proteins",

year = "1991",

language = "English",

volume = "21",

pages = "219--24",

journal = "European Journal of Clinical Investigation",

issn = "0014-2972",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma

AU - Kharazmi, A

AU - Nielsen, H

AU - Hovgaard, D

AU - Borregaard, N

AU - Nissen, N I

N1 - Keywords: Cell Degranulation; Chemotaxis, Leukocyte; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Luminescent Measurements; Lymphoma, Non-Hodgkin; Monocytes; Neutrophils; Recombinant Proteins

PY - 1991

Y1 - 1991

N2 - Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to inhibit the chemotaxis and enhance the oxidative burst response of human neutrophils in vitro. The present study describes the effect of recombinant GM-CSF on the neutrophil and monocyte function in patients with lymphoma undergoing GM-CSF treatment. Patients with either Hodgkin's or non-Hodgkin's lymphoma were treated with various dosages (2-16 micrograms kg-1 body weight per day for 5 days) of rhGM-CSF by intravenous or subcutaneous route. Prior to and on day 5 of rhGM-CSF treatment, neutrophil and monocyte chemotaxis and chemiluminescence responses to f-Met-Leu-Phe, zymosan activated serum (ZAS) and opsonized zymosan (OZ) were determined. It was observed that chemotactic response of neutrophils to f-Met-Leu-Phe and ZAS was reduced, whereas the chemiluminescence response of both cell types to f-Met-Leu-Phe and zymosan was enhanced by up to 43-fold. rhGM-CSF treatment did not affect degranulation of the neutrophils as measured by release of vitamin B12 binding protein. Degree of modulation of neutrophil and monocyte function by rhGM-CSF was independent of rhGM-CSF dosages administered. These data suggest that phagocytic defence system may be enhanced by GM-CSF treatment and that this cytokine may be a useful therapeutic adjunct in compromised patients.

AB - Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to inhibit the chemotaxis and enhance the oxidative burst response of human neutrophils in vitro. The present study describes the effect of recombinant GM-CSF on the neutrophil and monocyte function in patients with lymphoma undergoing GM-CSF treatment. Patients with either Hodgkin's or non-Hodgkin's lymphoma were treated with various dosages (2-16 micrograms kg-1 body weight per day for 5 days) of rhGM-CSF by intravenous or subcutaneous route. Prior to and on day 5 of rhGM-CSF treatment, neutrophil and monocyte chemotaxis and chemiluminescence responses to f-Met-Leu-Phe, zymosan activated serum (ZAS) and opsonized zymosan (OZ) were determined. It was observed that chemotactic response of neutrophils to f-Met-Leu-Phe and ZAS was reduced, whereas the chemiluminescence response of both cell types to f-Met-Leu-Phe and zymosan was enhanced by up to 43-fold. rhGM-CSF treatment did not affect degranulation of the neutrophils as measured by release of vitamin B12 binding protein. Degree of modulation of neutrophil and monocyte function by rhGM-CSF was independent of rhGM-CSF dosages administered. These data suggest that phagocytic defence system may be enhanced by GM-CSF treatment and that this cytokine may be a useful therapeutic adjunct in compromised patients.

M3 - Journal article

C2 - 1905635

SN - 0014-2972

VL - 21

SP - 219

EP - 224

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

IS - 2

ER -